Literature DB >> 15173098

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.

John W Park1, Robert S Kerbel, Gary J Kelloff, J Carl Barrett, Bruce A Chabner, David R Parkinson, Jonathan Peck, Raymond W Ruddon, Caroline C Sigman, Dennis J Slamon.   

Abstract

Mesh:

Substances:

Year:  2004        PMID: 15173098     DOI: 10.1158/1078-0432.CCR-03-0785

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  36 in total

1.  Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review.

Authors:  Michael A Vogelbaum; Daria Krivosheya; Hamid Borghei-Razavi; Nader Sanai; Michael Weller; Wolfgang Wick; Riccardo Soffietti; David A Reardon; Manish K Aghi; Evanthia Galanis; Patrick Y Wen; Martin van den Bent; Susan Chang
Journal:  Neuro Oncol       Date:  2020-11-26       Impact factor: 12.300

2.  Optimizing investigator-led oncology research in Europe.

Authors:  Tiziano Barbui; Magnus Björkholm; Alois Gratwohl
Journal:  Haematologica       Date:  2012-06       Impact factor: 9.941

Review 3.  Envisioning the future of early anticancer drug development.

Authors:  Timothy A Yap; Shahneen K Sandhu; Paul Workman; Johann S de Bono
Journal:  Nat Rev Cancer       Date:  2010-06-10       Impact factor: 60.716

4.  3D Slicer as an image computing platform for the Quantitative Imaging Network.

Authors:  Andriy Fedorov; Reinhard Beichel; Jayashree Kalpathy-Cramer; Julien Finet; Jean-Christophe Fillion-Robin; Sonia Pujol; Christian Bauer; Dominique Jennings; Fiona Fennessy; Milan Sonka; John Buatti; Stephen Aylward; James V Miller; Steve Pieper; Ron Kikinis
Journal:  Magn Reson Imaging       Date:  2012-07-06       Impact factor: 2.546

Review 5.  Translational research in phase I trials.

Authors:  Angelica Fasolo; Cristiana Sessa
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

Review 6.  Clinical applications of metabolomics in oncology: a review.

Authors:  Jennifer L Spratlin; Natalie J Serkova; S Gail Eckhardt
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

7.  Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy.

Authors:  David S Hong; Goldy C George; Eucharia C Iwuanyanwu; Bahareh Tavana; Gerald S Falchook; Sarina A Piha-Paul; Jennifer J Wheler; Reena H Mistry; Xiudong Lei; Razelle Kurzrock
Journal:  J Cancer Res Clin Oncol       Date:  2013-03-02       Impact factor: 4.553

Review 8.  Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.

Authors:  Frank S Ong; Kingshuk Das; Jay Wang; Hana Vakil; Jane Z Kuo; Wendell-Lamar B Blackwell; Stephen W Lim; Mark O Goodarzi; Kenneth E Bernstein; Jerome I Rotter; Wayne W Grody
Journal:  Expert Rev Mol Diagn       Date:  2012-07       Impact factor: 5.225

Review 9.  Validation of analytic methods for biomarkers used in drug development.

Authors:  Cindy H Chau; Olivier Rixe; Howard McLeod; William D Figg
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

10.  A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment.

Authors:  Sheila E Taube; Gary M Clark; Janet E Dancey; Lisa M McShane; Caroline C Sigman; Steven I Gutman
Journal:  J Natl Cancer Inst       Date:  2009-10-23       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.